Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy.
Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups.
Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use.
Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.